Moderna’s COVID-19 pledge dilemma

As the company challenges Pfizer and BioNTech over COVID-19 vaccine patents, issues over the enforceability of pledges made during the pandemic may make pharma think twice in future, finds Marisa Woutersen.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Europe

UPC dispute resolution forum opens with ceremony in Slovenia

2 June 2026 The court has officially opened its mediation and arbitration forum, with technology, life sciences and manufacturing companies expected to be among its earliest users—particularly in FRAND and licensing cases.

Europe

European court backs AstraZeneca unit in blood cancer combo dispute

28 May 2026 A European court dismissed a challenge by a German generics manufacturer, confirming the validity of a patent covering a blood cancer combination therapy.

Europe

Chinese medtech company fined by UPC over injunction breaches

21 May 2026 The court has imposed a financial penalty after finding it continued promoting banned devices online despite an injunction covering five European countries.

More features

Hikma triumphs at SCOTUS in landmark skinny-label ruling

Pfizer strikes $10.5 billion oncology deal with Chinese biotech

Dehns appoints head of litigation following wave of senior hires

Heated LNP litigation puts Moderna and Acuitas in the spotlight

UPC dispute resolution forum opens with ceremony in Slovenia

J&J unit's valuable heart pump saved by 'rare' patent defence

Kirkland & Ellis adds leading barrister in London

Federal Circuit tosses $59m trade secrets judgment against EOFlow

Moderna’s COVID-19 pledge dilemma

More on this story

Editor's picks

Editor's picks

More features